102,085 Urogen Pharma $URGN Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. reduced its stake in shares of Urogen Pharma (NASDAQ:URGN) by 48.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 107,915 shares of the company’s stock after selling 102,085 shares during the period. Urogen Pharma accounts for about 0.8% of Privium Fund Management B.V.’s investment portfolio, making the stock its 26th largest position. Privium Fund Management B.V.’s holdings in Urogen Pharma were worth $4,385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Urogen Pharma in the second quarter worth approximately $117,814,000. Jefferies Financial Group Inc. acquired a new position in Urogen Pharma during the second quarter worth approximately $80,947,000. Opaleye Management Inc. increased its position in Urogen Pharma by 0.7% during the second quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock worth $52,992,000 after purchasing an additional 9,996 shares during the last quarter. Bank of America Corp DE acquired a new position in Urogen Pharma during the second quarter worth approximately $17,506,000. Finally, Rice Hall James & Associates LLC purchased a new position in Urogen Pharma during the second quarter worth approximately $11,064,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.77 from a loss of $0.83, and lifted its Q4 2026 and Q1 2027 forecasts to $0.02 per share. The firm maintained its Buy rating and $75 target. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Sell-side brokerages collectively rate URGN “Moderate Buy,” though that consensus provides limited near-term direction. Urogen Pharma Stock Now Rated Moderate Buy
• Negative Sentiment: HC Wainwright cut its FY2027 EPS forecast to $0.59 from $1.05, lowering estimates for Q2, Q3 and Q4 2027 as well. The reductions suggest a less favorable profit outlook, despite the firm’s unchanged Buy rating and target.
• Negative Sentiment: The latest quarterly results missed expectations: UroGen reported a $0.03-per-share loss versus consensus earnings of $0.11, while revenue of $89 million was slightly below estimates. Reports said shares fell sharply after the results and slipped below their 200-day moving average. Shares Break Below Two Hundred Day Moving Average on Disappointing Earnings

Wall Street Analysts Forecast Growth

URGN has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Urogen Pharma in a report on Monday, October 19th. TD Cowen upped their price objective on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Oppenheimer set a $60.00 price objective on Urogen Pharma in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Finally, Guggenheim reduced their target price on Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.38.

Insider Activity

In related news, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the transaction, the general counsel owned 53,141 shares in the company, valued at approximately $2,260,618.14. The trade was a 2.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Schoenberg sold 60,677 shares of Urogen Pharma stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider owned 59,086 shares in the company, valued at $2,779,996.30. The trade was a 50.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 65,269 shares of company stock valued at $3,037,646. Company insiders own 4.80% of the company’s stock.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN traded down $0.98 during trading on Friday, reaching $24.75. 1,758,050 shares of the stock were exchanged, compared to its average volume of 1,169,568. The firm’s 50-day moving average price is $38.78 and its 200 day moving average price is $31.53. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -18.75 and a beta of 1.68. Urogen Pharma has a 12-month low of $16.50 and a 12-month high of $50.81.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.14). The business had revenue of $89.00 million for the quarter, compared to the consensus estimate of $89.92 million. As a group, equities research analysts forecast that Urogen Pharma will post -0.20 EPS for the current year.

Urogen Pharma Company Profile

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.